Home · Health · Sep 30 archive
New Score Better at Identifying Low HCC Risk in Cirrhosis Patients
Developing
In Short: According to the study authors, THRI could be used to inform personalized HCC surveillance strategies, particularly in aiding decisions to defer surveillance in low-risk patients with cirrhosis.
A multicenter cohort study has revealed that the Toronto hepatocellular carcinoma (HCC) risk index (THRI), a score based on routine patient data and the etiology of cirrhosis, is more effective in identifying patients with cirrhosis who have a near-negligible 5-year risk of developing HCC compared to the aMAP risk-stratification score.
According to the study authors, THRI could be used to inform personalized HCC surveillance strategies, particularly in aiding decisions to defer surveillance in low-risk patients with cirrhosis.
The analysis found that among patients classified as low-risk by the aMAP score, approximately two-thirds were reclassified as higher risk by THRI and had a substantially higher 5-year HCC incidence than those classified as low-risk by both scores.
The study evaluated only the THRI and aMAP score and did not assess other HCC risk-prediction models or biomarker-based approaches.
What this adds
The study highlights the potential of THRI to improve personalized HCC surveillance strategies, but it does not compare THRI with other risk-prediction models or biomarker-based approaches.
What's still developing
- Nothing material beyond the confirmed record.